Optimization of irinotecan chronotherapy with P-glycoprotein inhibition

Toxicology and Applied Pharmacology

Volumn 274, Issue 3, 2014, Pages 471-479

  Filipski, Elisabeth ^a,b   Berland, Elodie ^a,b   Ozturk, Narin ^a,b,d   Guettier, Catherine ^c   van der Horst, Gijsbertus T J ^e   Lévi, Francis ^a,b,c   Okyar, Alper ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d ISTANBUL UNIVERSITY   (Turkey)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer chronotherapy; Circadian rhythm; Irinotecan; P glycoprotein; PSC833

Indexed keywords

IRINOTECAN; MESSENGER RNA; VALSPODAR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CHRONOTHERAPY; CONTROLLED STUDY; DRUG INHIBITION; DRUG TOLERABILITY; FEMALE; ILEUM MUCOSA; LEUKOPENIA; MOUSE; NONHUMAN; OSTEOSARCOMA; TREATMENT DURATION; TUMOR CELL LINE; WEIGHT CHANGE; WEIGHT REDUCTION;

CANCER CHRONOTHERAPY; CIRCADIAN RHYTHM; IRINOTECAN; P-GLYCOPROTEIN; PSC833;

ANIMALS; BODY WEIGHT; CAMPTOTHECIN; CELL LINE, TUMOR; CHRONOTHERAPY; CIRCADIAN RHYTHM; CYCLOSPORINS; ENDPOINT DETERMINATION; FEMALE; ILEUM; MICE; MUCOUS MEMBRANE; OSTEOSARCOMA; P-GLYCOPROTEIN; RNA, MESSENGER; TIME FACTORS;

EID: 84892456479     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2013.12.018     Document Type: Article

References (54)

1. Achira M., Ito K., Suzuki H., Sugiyama Y. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci. art 18 1999, 1(4):1-6.
2. Ahowesso C., Li X.M., Zampera S., Peteri-Brunbäck B., Dulong S., Beau J., Hossard V., Filipski E., Delaunay F., Claustrat B., Lévi F. Sex and dosing time dependencies in irinotecan-induced circadian disruption. Chronobiol. Int. 2011, 28:458-470.
3. Ando H., Yanagihara H., Sugimoto K., Hayashi Y., Tsuruoka S., Takamura T., Kaneko S., Fujimura A. Daily rhythms of P-glycoprotein expression in mice. Chronobiol. Int. 2005, 22:655-665.
4. Baer M.R., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., Anastasi J., Powell B.L., Kolitz J.E., Schiffer C.A., Bloomfield C.D., Larson R.A. Phase III study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002, 100:1224-1232.
5. Ballesta A., Dulong S., Abbara C., Cohen B., Okyar A., Clairambault J., Lévi F. A combined experimental and mathematical approach for molecular-based optimization of irinotecan circadian delivery. PLoS Comput. Biol. 2011, 7(9):e1002143. 10.1371/journal.pcbi.1002143.
6. Bansal T., Mishra G., Jaggi M., Khar R.K., Talegaonkar S. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur. J. Pharm. Sci. 2009, 36:580-590.
7. Bissery M.C., Vrignaud P., Lavelle F., Chabot G.G. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996, 7:437-460.
8. Boote D.J., Dennis I.F., Twentyman P.R., Osborne R.J., Laburte C., Hensel S., Smyth J.F., Brampton M.H., Bleehen N.M. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 1996, 14:610-618.
9. Cagliero E., Ferracini R., Morello E., Scotlandi K., Manara M.C., Buracco P., Comandone A., Baroetto-Paris R., Baldini N. Reversal of multidrug-resistance using valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol. Rep. 2004, 12:1023-1031.
10. Chomczynski P., Sacchi N. The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protoc. 2006, 1:581-585.
11. Chu X.Y., Kato Y., Sugiyama Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Drug Metab. Dispos. 1999, 27:440-441.
12. Claudel T., Cretenet G., Saumet A., Gachon F. Crosstalk between xenobiotics metabolism and circadian clock. FEBS Lett. 2007, 581:3626-3633.
13. Cufer T., Vrhovec I., Pfeifer M., Skrk J., Borstnar S., Sikic B. Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits. Cancer Chemother. Pharmacol. 1998, 41:517-521.
14. De Prins J., Hecquet B. Biological Rhythms in Clinical and Laboratory Medicine 1992, 90-112. Springer Verlag, Berlin. Y. Touitou, E. Haus (Eds.).
15. Dibner C., Schibler U., Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clock. Annu. Rev. Physiol. 2010, 72:517-549.
16. Filipski E., Lemaigre G., Liu X.H., Mery-Mignard D., Mahjoubi M., Lévi F. Circadian rhythm of irinotecan tolerability in mice. Chronobiol. Int. 2004, 21:613-630.
17. Filipski E., Innominato P.F., Wu M., Li X.M., Iacobelli S., Xian L.J., Lévi F. Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl. Cancer Inst. 2005, 97:507-517.
18. Gachon F., Olela F.F., Schaad O., Descombes P., Schibler U. The circadian PAR domain basic leucine zipper transcription factors DBP, TEF, and HLF modulate basal and inducible xenobiotic detoxification. Cell Metab. 2006, 4:25-36.
19. Giacchetti S., Dugué P.A., Innominato P.F., Bjarnason G.A., Focan C., Garufi C., Tumolo S., Coudert B., Iacobelli S., Smaaland R., Tampellini M., Adam R., Moreau T., Lévi F. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann. Oncol. 2012, 23:3110-3116.
20. Granda T.G., D'Attino R.M., Filipski E., Vrignaud P., Garufi C., Terzoli E., Bissery M.C., Lévi F. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 2002, 86:999-1005.
21. Greenberg P.L., Lee S.J., Advani R., Tallman M.S., Sikic B.I., Letendre L., Dugan K., Lum B., Chin D.L., Dewald G., Paietta E., Bennett J.M., Rowe J.M. Mitoxantrone, etoposide and cytarabine with or without valspodar in patients with relapsed or refractory acute myelod leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J. Clin. Oncol. 2004, 22:1078-1086.
22. Innocenti F., Ratain M.J. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park) 2003, 17(Suppl. 5):52-55.
23. Iurisci I., Filipski E., Reinhardt J., Bach S., Gianella-Borradori A., Iacobelli S., Meijer L., Lévi F. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 2006, 66:10720-11028.
24. Iyer L., Ramírez J., Shepard D.R., Bingham C.M., Hossfeld D.K., Ratain M.J., Mayer U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol. 2002, 49:336-341.
25. Johnson B.M., Charman W.N., Porter C.J. Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab. Dispos. 2003, 31:1151-1160.
26. Kankesan J., Yusuf A., Laconi E., Vanama R., Bradley G., Thiessen J., Ling V., Rao P., Rajalakshmi S., Sarma D.S.R. Effect of PSC833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats. Carcinogenesis 2003, 24:1977-1984.
27. Kankesan J., Vanama R., Yusuf A., Thiessen J., Ling V., Rao P., Rajalakshmi S., Sarma D.S.R. Effect of PSC833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats. Carcinogenesis 2004, 25:425-430.
28. Kankesan J., Laconi E., Medline A., Thiessen J., Ling V., Rao P.M., Rajalakshmi S., Sarma D.S.R. PSC833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine-induced colorectal carcinogenesis in male Fischer F344 rats. Anticancer Res. 2006, 26:995-999.
29. Kemper E.M., van Zandbergen A.E., Cleypool C., Mos H.A., Boogerd W., Beijnen J.H., van Tellingen O. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. 2003, 9:2849-2855.
30. Kolitz J.E., George S.L., Dodge R.K., Hurd D.D., Powell B.L., Allen S.L., Velez-Garcia E., Moore J.O., Shea T.C., Hoke E., Caligiuri M.A., Vardiman J.W., Bloomfield C.D., Larson R.A. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60years: final induction results of Cancer and Leukemia Group B Study 9621. J. Clin. Oncol. 2004, 22:4290-4301.
31. Krishna R., Mayer L.D. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res. 1999, 19(4B):2885-2891.
32. Lévi F. Chronotherapeutics: the relevance of timing in cancer therapy. Cancer Causes Control 2006, 17:611-621.
33. Lévi F., Okyar A. Circadian clocks and drug delivery systems: impact and opportunities in chronotherapeutics. Expert Opin. Drug Deliv. 2011, 8:1535-1541.
34. Lévi F., Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 2007, 47:593-628.
35. Lévi F., Zidani R., Misset J.L. Randomized multicenter trial of chronotherapy with oxaliplatin, 5-fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997, 350:681-686.
36. Lévi F., Focan C., Karaboué A., de la Valette V., Focan-Henrard D., Baron B., Kreutz F., Giacchetti S. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv. Drug Deliv. Rev. 2007, 59:1015-1035.
37. Lévi F., Altinok A., Clairambault J., Goldbeter A. Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Philos. Trans. R. Soc. A 2008, 366:3575-3598.
38. Lévi F., Okyar A., Dulong S., Innominato P.F., Clairambault J. Circadian timing in cancer treatment. Annu. Rev. Pharmacol. Toxicol. 2010, 50:377-410.
39. Li X.M., Mohammad-Djafari A., Dumitru M., Dulong S., Filipski E., Siffroi-Fernandez S., Mteyrek A., Scaglione F., Guettier C., Delaunay F., Lévi F. A circadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 2013, 73(24). (Epub ahead of print). 10.1158/0008-5472.CAN-13-1528.
40. Luo F.R., Paranjpe P.V., Guo A., Rubin E., Sinko P. Intestinal transport of irinotecan in Caco-2 cells and MDCK II cells overexpressing efflux transporters Pgp, cMOAT, and MRP1. Drug Metab. Dispos. 2002, 30(7):763-770.
41. Murakami Y., Higashi Y., Matsunaga N., Koyanagi S., Ohdo S. Circadian clock controlled intestinal expression of the multidrug-resistance gene mdr1a in mice. Gastroenterology 2008, 135:1636-1644.
42. Nakagawa M., Terashima T., D'yachkova Y., Bondy G., Hogg J., van Eeden S. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 1998, 98:2307-2313.
43. Ohdo S., Makinosumi T., Ishizaki T., Yukawa E., Higuchi S., Nakano S., Ogawa N. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J. Pharmacol. Exp. Ther. 1997, 283:1383-1388.
44. Okyar A., Piccolo E., Ahowesso C., Filipski E., Hossard V., Guettier C., La Sorda R., Tinari N., Iacobelli S., Lévi F. Strain- and sex-dependent circadian changes in abcc2 transporter expression: implications for irinotecan chronotolerance in mouse ileum. PLoS One 2011, 10.1371/journal.pone.0020393.
45. Okyar A., Dressler C., Hanafy A., Baktir G., Lemmer B., Spahn-Langguth H. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance. Chronobiol. Int. 2012, 29(4):443-453.
46. Page R.L., Hughes C.S., Huyan S., Sagris J., Trogdon M. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines. Anticancer Res. 2000, 20(5B):3533-3538.
47. Song S., Suzuki H., Kawai R., Sugiyama Y. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab. Dispos. 1999, 27:689-694.
48. Sonneveld P., Sauci S., Weijermans P., Beksac M., Neuwirtova R., Solbu G., Lokhorst H., van der Lelie J., Dohner H., Gerhartz H., Segeren C.M., Willemze R., Lowenberg B. Cyclosporine A combined with vincristine, doxorubicine and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma. Br. J. Haematol. 2001, 115:895-902.
49. Szakács G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesmann M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 3:219-234.
50. Tai H.L. Technology evaluation: Valspodar, Novartis AG. Curr. Opin. Mol. Ther. 2000, 2:459-467.
51. Tampellini M., Filipski E., Liu X.H., Lemaigre G., Li X.M., Vrignaud P., François E., Bissery M.C., Lévi F. Docetaxel chronopharmacology in mice. Cancer Res. 1998, 58:3896-3904.
52. van der Holt B., Löwenberg B., Burnett A.K., Knauf W.U., Shepherd J., Piccaluga P.P., Ossenkoppele G.J., Verhoef G.E., Ferrant A., Crump M., Selleslag D., Theobald M., Fey M.F., Vellenga E., Dugan M., Sonneveld P. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 2005, 106(8):2646-2654.
53. Watanabe T., Tsuge H., Oh-Hara T., Naito M., Tsuruo T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol. 1995, 34:235-241.
54. Zhang Y.K., Yeager R.L., Klaassen C.D. Circadian expression profiles of drug-processing genes and transcription factors in mouse liver. Drug Metab. Dispos. 2009, 3:106-115.